This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "GABARNANCE Trial - Gemcitabine + nab-Paclitaxel vs. CRT With S-1 as Neoadjuvant Treatment for Borderline Resectable Pancreatic Cancer"

40 views
June 18, 2024
Comments 0
Login to view comments. Click here to Login